Abbott Laboratories
ABT · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $196 | $191 | $192 | $250 |
| - Cash | $8 | $7 | $10 | $10 |
| + Debt | $15 | $16 | $18 | $19 |
| Enterprise Value | $204 | $200 | $201 | $259 |
| Revenue | $42 | $40 | $44 | $43 |
| % Growth | 4.6% | -8.1% | 1.3% | – |
| Gross Profit | $21 | $20 | $22 | $23 |
| % Margin | 50.8% | 50% | 51.1% | 53.9% |
| EBITDA | $11 | $11 | $12 | $12 |
| % Margin | 25.8% | 26.4% | 27.2% | 28.2% |
| Net Income | $13 | $6 | $7 | $7 |
| % Margin | 31.9% | 14.3% | 15.9% | 16.4% |
| EPS Diluted | 7.64 | 3.27 | 3.91 | 3.94 |
| % Growth | 133.6% | -16.4% | -0.8% | – |
| Operating Cash Flow | $9 | $7 | $10 | $11 |
| Capital Expenditures | -$2 | -$2 | -$2 | -$2 |
| Free Cash Flow | $6 | $5 | $8 | $9 |